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This study compared drug coverage and
prescription drug use by race and Hispanic
ethnicity for Medicare beneficiaries with
three chronic conditions: diabetes, hyper-
tension, or heart disease. We found that
among beneficiaries without any drug cov-
erage black persons and Hispanics used 10
to 40 percent fewer medications, on aver-
age, than white persons with the same ill-
ness, and spent up to 60 percent less in total
drug costs. Having drug coverage some-
what lessened these dif ferences although the
ef fect was consistent with only M+C pre-
scription benefits. Substantially lower med-
ication use remained for dually eligible
black beneficiaries and Hispanics with
employer-sponsored drug benefits.
INTRODUCTION
This study examines the access that
black and Hispanic Medicare beneficiaries
have to prescribed drugs for chronic con-
ditions. We know little about how race and
ethnicity influences medication use despite
substantial research showing that, for most
health care services, minority beneficiaries
use fewer services compared with white
persons (Gornick, 1999, 2000, 2003;
Gornick et al., 1996; Gornick, Eggers, and
Riley, 2001; Murray, 2000). One exception
to this pattern—and a possible indicator of
medication underuse—is a higher than
average need for procedures used to treat
the complications of chronic illnesses. For
instance, elderly black beneficiaries are
three to four times more likely than white
beneficiaries to undergo amputations of
lower limbs or implantations of shunts for
renal dialysis due to uncontrolled diabetes
(Gornick, 1999, 2000; Gornick et al., 1996).
Such differences have been generally
interpreted as evidence of widespread
insensitivity in the acute care setting
(Mayberry, Mili, and Ofili, 2000). An alter-
native explanation is that minority benefi-
ciaries may be facing persistent problems
in getting necessary medications that
eventually lead to the most debilitating
effects of unmanaged chronic illness. 
Black and Hispanic Medicare beneficia-
ries may be particularly susceptible to
medication underuse for economic rea-
sons because outpatient prescription drugs
will not be included under the traditional
Medicare benefit until 2006. Until then,
beneficiaries must negotiate some form of
drug benefits or else pay out-of-pocket for
their medication expenses. Options for
gaining drug coverage include earning
comprehensive retiree health benefits,
buying personal insurance, enrolling into
M+C plans with a drug coverage option, or
qualifying for public assistance (e.g.,
Medicaid or State pharmaceutical assis-
tance programs). Some of these avenues
may be less accessible to minority popula-
tions, while other types place considerable
demands on personal income and savings.
For example, private drug plans often require
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substantial cost sharing in the form of
copayments for each prescription fill,
deductibles, and monthly premiums.
Access to employer-sponsored drug cover-
age depends on consistent employment
opportunities in industries offering retiree
benefits. Enrollment into M+C plans with
drug coverage has becoming increasingly
limited for residents of Southern States
where many minorities live. Similarly, only
three States offer substantial drug assis-
tance programs for Medicare beneficiaries,
and they are all in the Northeast (New
Jersey, New York, and Pennsylvania). For
chronically-ill black and Hispanic benefi-
ciaries with regular medical needs and
scarce personal resources, inadequate
drug coverage may translate to disparities
in medication use.
Few studies have compared racial dis-
parities in medication use by drug insur-
ance status despite the intuitive relation-
ship between affording drug therapies and
managing disease (Espino et al., 1998;
Fillenbaum et al., 1993; Fillenbaum et al.,
1996; Nelson, Norris, and Mangione, 2002;
Svetkey et al., 1996; White-Means, 2000).
We used the wide variation in prescription
drug coverage among Medicare beneficia-
ries to study prescription spending and use
by race and Hispanic ethnicity for three
groups with persistent medication needs—
those with diabetes, hypertension, or heart
disease. Cardiovascular disease and dia-
betes are two of three chronic conditions
(the third is HIV/AIDS) identified as tar-
gets for Federal initiatives to eliminate
racial/ethnic disparities in health (U.S.
Department of Health and Human
Services, 1999). We also examined benefi-
ciaries with hypertension as a condition
commonly identified as sensitive to race
and ethnicity, in terms of disease preva-
lence, treatment selection, and health care
use (Sung et al., 1997). All three conditions
are commonly treated with drug therapy to
minimize the debilitating effects of pro-
gressive disease. Our main objective was
to distinguish whether drug coverage
lessens or eliminates racial and ethnic dif-
ferences in the use of medications for
chronic conditions, and whether certain
types of coverage are more effective at
improving access.
METHODS
Data
We used data from the 1999 MCBS Cost
and Use File to study prescription drug
coverage, expenditures, and use across dif-
ferent race and ethnic groups. The MCBS
is a longitudinal panel survey of a repre-
sentative national sample of the Medicare
population conducted under the auspices
of CMS. Beginning in fall 1991, more than
12,000 Medicare beneficiaries have been
interviewed three times a year using com-
puter-assisted personal interviewing. Each
respondent is followed for up to 4 years.
MCBS interviewers collect extensive infor-
mation on individuals’ use and expendi-
tures for health services including source
of payment, as well as information on
health insurance, access to care, health
and functional status, socioeconomic sta-
tus, and demographic characteristics.
Prescription drug utilization data in the
MCBS are based on self-reports of each
prescription filled and refilled during the
year. To assure accurate recall, respon-
dents are asked to keep bill records and
prescription containers to show interview-
ers during the three yearly interviews.
Sample
Our sample consisted of non-institution-
alized Medicare beneficiaries age 65 or
over who identified their race and Hispanic
ethnicity in the survey. American Indians,
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Asians, or Pacific Islanders were excluded
because their sample sizes were insuffi-
cient to provide reliable estimates.  In addi-
tion, we excluded persons who did not pro-
vide specific racial/ethnicity information.
We created three mutually-exclusive racial
and ethnicity groups: non-Hispanic white,
non-Hispanic black, and Hispanic. These
categories conform to recommendations
by minority health task groups to identify
Hispanic Americans independently from
race (Zambrana and Carter-Pokras, 2001).
We used self-reports of diseases to identify
individuals with diabetes, hypertension, or
heart disease. Prior study has shown that
accuracy of self-reported health varies by
medical conditions, but is generally not
sensitive to race or ethnicity (Bergmann et
al., 1998). In comparing our three disease
groups, we found a large overlap among
hypertensive beneficiaries who also reported
heart disease and/or diabetes. Thus, our
analysis of persons with hypertension
excludes those who also had heart disease
or diabetes. Our unweighted samples sizes
are: 4,355 beneficiaries with heart disease
(n=3,760 white persons, n=334 black per-
sons, n=261 Hispanics), 1,568 with dia-
betes (n=1,196 white persons, n=218 black
persons, n=154 Hispanics), and 2,157 with
hypertension (n=1,762 white persons,
n=235 black persons, n=160 Hispanics). 
Statistical Analysis
Our analysis examined five measures of
prescription use and expenditures: (1)
annual number of prescriptions filled, (2)
total prescription cost, (3) average unit
price (ratio of total prescription cost over
number of prescription filled), (4) out-of-
pocket costs, and (5) use of medications
from broad therapeutic classes commonly
recommended in the management of the
study condition. These include oral hypo-
glycemic drugs and hormones such as
insulin for diabetes, and cardiac agents,
cardiovascular drugs and diuretics for
hypertension and heart disease. Our main
study variables were indicator variables of
race and Hispanic ethnicity. We further
classified each group by source of pre-
scription drug coverage. For covariates we
included socioeconomic traits (age, sex,
and income relative to the FPL) and sever-
al measures of health status: self-rated
health status, number of comorbidities,
and limitations in daily living activities or
instrumental activities of daily living. 
We calculated descriptive statistics of
selected personal characteristics, prescrip-
tion use, and expenditures for each disease
group stratified by race and ethnicity and
source of drug coverage. In our bivariate
analyses, we tested for statistically signifi-
cant differences in prescription use of
black persons relative to white persons and
Hispanics relative to white persons. For
the multivariate models, we limited our
sample to people with any drug use and
one of four types of drug coverage: no drug
coverage, Medicaid, employer-sponsored
plans, or M+C. (Our models excluded per-
sons with Medigap drug plans or other
public drug assistance programs due to
small sample sizes.) We then estimated
four identically specified linear and logistic
regressions: 
y = α + β1x1 + β2x2 + e
where (y) in the linear form takes the
logged form of the number of medications,
total medication costs, and out-of-pocket
costs, (α) is the constant, (x1) is a set of
dummy indicators for black persons and
Hispanic ethnicity, (x2) is a set of covariates
previously described, and e is an error term.
For the logistic regression, (y) is a binary
variable indicating whether beneficiaries
HEALTH CARE FINANCING REVIEW/Winter 2003-2004/Volume 25, Number 2 65
received recommended drug treatments
and (x1) and (x2) are the same as in the lin-
ear regressions.
Each set of models was run separately
for each disease group and stratified by
major type of drug coverage for a total of
48 models (three disease groups by four
drug coverage types by four outcome mea-
sures). This approach was taken to isolate
any racial or ethnic disparities in medica-
tion use among people with the same dis-
ease and same type of drug coverage.
Preliminary analyses showed that the aver-
age effect of insurance status varied con-
siderably by race/ethnicity and type of ill-
ness, which prohibited simple pooled
regressions. In each model we examined
the relative differences in prescription
expenditures and utilization of black per-
sons and Hispanics compared with white
persons. Diagnostic tests included an over-
all Chow test for statistically different coef-
ficients and variance for the three racial/
ethnic groups (F=6.11, p <0.001). All
regressions were statistically significant,
and the R-squared ranged from 8 to 19 per-
cent). (Regression outputs are available
from the authors upon request.) All analy-
ses used survey estimator modules in
STATA® Software Version 7 (Stata, College
Station, TX) to estimate standard errors in
the population weighted analyses. 
RESULTS
Sample Description
In 1999, the size of the Medicare popula-
tion age 65 or over and living in the com-
munity numbered approximately 31 mil-
lion people (26.6 million white persons, 2.3
million black persons, and about 2.0 mil-
lion Hispanics) (Table 1). Among them,
nearly one-half (43.6 percent) reported
having some form of heart disease, anoth-
er 20 percent had uncomplicated hyperten-
sion, and 16 percent had diabetes. The
prevalence of heart disease and hyperten-
sion was roughly similar across the three
racial/ethnic groups except for diabetes
which is far more common in minority ben-
eficiaries: one in four black and Hispanic
beneficiaries reported having diabetes
compared with only 15 percent of white
beneficiares. The rest of this table shows
how beneficiaries with chronic illnesses
(especially those with heart disease and
diabetes) had socio-economic and health
disadvantages compared with the general
Medicare population. Beneficiaries with
heart disease, hypertension, or diabetes
were generally older than the average ben-
eficiary, and they more often had incomes
below the FPL. About one-third of benefi-
ciaries with heart disease and diabetes
described their health as fair or poor com-
pared with about one-fifth of the total
group. Lastly, the vast majority (97 to 82
percent) of the three disease groups had
other chronic illnesses in addition to their
study condition. 
Prescription Drug Coverage
Table 2 describes the different sources
of drug coverage for beneficiaries with dia-
betes, hypertension, or heart disease.
Although most white, black, and Hispanic
Medicare beneficiaries maintained some
form of prescription drug coverage in
1999, the type of coverage differed greatly.
In general, minorities relied far more heav-
ily than the white individuals on public pro-
grams for assistance with prescription
drug costs. Between 25-29 percent of
Hispanic and black beneficiaries received
drug benefits from Medicaid—through
either traditional Medicaid or the Qualified
Medicare Beneficiary Plus (QMB+) pro-
grams—compared with only 5 percent of
white persons. Other public drug coverage
was more comparable across the three
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groups through sources such as the
Department of Veterans Affairs and State-
funded pharmacy assistance programs,
which ranged from 12 to 17 percent.
Conversely, minority beneficiaries were
less likely to have private sources of drug
coverage. For instance, in 1999 only 12 per-
cent of Hispanics and 25 percent of black
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Table 1
Select Characteristics of Medicare Beneficiaries, by Chronic Conditions: 1999
Characteristic All Diabetes Heart Disease1 Hypertension2
Total (in Millions) 30.656 4.916 13.485 7.052
Percent by Race/Ethnicity
White 85.6 78.0 87.1 82.7
Black 7.6 12.0 7.0 9.5
Hispanic 6.7 10.0 5.9 7.8
Age
65-69 Years 25.0 22.8 20.3 22.8
70-74 Years 26.5 30.6 24.5 26.3
75-79 Years 22.8 24.0 25.2 24.4
80 Years or Over 25.6 22.6 30.0 26.5
Sex
Female 57.8 53.9 54.8 63.5
Income as Percent of FPL
≤100 20.4 24.9 21.1 19.6
101-200 31.5 34.1 33.4 31.3
>200 48.1 41.0 45.5 49.1
Self-Reported Health Status
Poor 6.7 10.3 8.7 3.0
Fair 16.9 23.9 22.0 13.0
Good/Excellent 78.2 65.8 69.3 84.0
Burden of Chronic Conditions3
1 16.4 3.3 4.3 18.1
2 23.8 12.2 16.3 42.0
3 or More 51.2 84.5 79.4 39.9
1 Includes individuals reporting they have been told they have angina/coronary heart disease, myocardial infarction, atherosclerosis, or other heart
disease.
2 Includes individuals reporting they have been told that they have hypertension. It excludes hypertensive individuals with diabetes and/or heart 
disease.
3 Chronic conditions include self-reported conditions of hypertension, stroke, heart disease (angina/coronary heart disease, myocardial infarction, 
atherosclerosis, other heart disease), diabetes, arthritis (osteoarthritis, rheumatoid arthritis), Alzheimer’s disease, osteoporosis, mental disorder, lung
disorder (emphysema, chronic obstructive pulmonary disease, asthma), and cancer.
NOTE: Excludes beneficiaries with end stage renal disease entitlement.
SOURCE: Centers for Medicare & Medicaid Services: Data from the Medicare Current Beneficiary Survey Cost and Use File, 1999.
Table 2
Prescription Drug Coverage of Medicare Beneficiaries with Chronic Conditions1, by
Race/Ethnicity: 1999
Beneficiaries
Coverage2 White Black Hispanic
Percent
M+C 17.7 **21.1 **25.2
Medicaid 5.0 **24.9 **29.3
Employer Sponsored 38.2 **25.9 **12.6
Medigap 15.6 ** 7.3 ** 6.7
Other3 12.5 **17.0 **15.6
No Coverage 23.7 **21.3 **23.1
** p<0.05 black non-Hispanics compared with white non-Hispanics and Hispanics compared with white non-Hispanics.
1 Chronic conditions: diabetes, hypertension, or heart disease.
2 Categories are not mutually exclusive.
3 Includes other public (such as State-funded prescription assistance program and Department of Veterans Affairs) and unknown source.
NOTE: n=22.6 million.
SOURCE: Centers for Medicare & Medicaid Services: Data from the Medicare Current Beneficiary Survey Cost and Use File, 1999.
beneficiaries obtained drug coverage from
employer-based insurance, compared with
over 38 percent of white beneficiaries. White
persons are also far more likely to have
Medigap drug coverage, at rates two and
three times higher than black persons and
Hispanics, respectively. Only M+C coverage
favors minority populations: Hispanics and
black persons more often had drug coverage
from Medicare HMOs than white persons
(25.2 and 21.1 percent versus 17.7 percent). 
Prescription Use and Expenditures by
Diseases
In Table 3, we see how drug coverage
influences the medication use and spend-
ing of diabetic beneficiaries by race and
ethnicity. Without any drug coverage,
white persons used one-third more med-
ications, on average, than black persons
and Hispanics, and spent 20 to 40 percent
more, respectively. Hispanic beneficiaries
tended to fill more expensive medications
although white persons had the best
access to diabetic agents: nearly 70 percent
took insulin or oral diabetic agents during
the year compared with only about 50 per-
cent of black persons (p<0.05) or Hispanics
(p<0.05). Having drug coverage somewhat
lessened these differences although the
effect was consistent with only managed
care benefits. For minority beneficiaries
with Medicaid drug benefits, medication
use remained much lower than for white
beneficiaries, although average prescription
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Table 3
Prescription Use and Expenditures for Medicare Beneficiaries with Diabetic Conditions1, by Drug
Coverage and Race/Ethnicity: 1999
Beneficiaries
Coverage2 White Black Hispanic
Total (in Millions) 3.84 0.6 0.47
No Coverage
Average Annual Drug Use 31.2 25.2 25.2
Average Unit Price $37.50 **$28.40 $31.70 
Average Out-of-Pocket Cost $1,095.40 **$670.5 $889.53 
Percent Out-of-Pocket to Total Cost 97.8 93.7 100.0
Percent Prevalence of Any Diabetic Drug Use2 69.9 **45.0 **52.3
Medicaid 
Average Annual Drug Use 51.6 39.6 39.6
Average Unit Price $32.00 $35.10 $33.50 
Average Out-of-Pocket Cost $334.80 *$182.50 $181.90 
Percent Out-of-Pocket to Total Cost 27.9 19.2 18.2
Percent Prevalence of Any Diabetic Drug Use2 71.20 **49.5 **73.2
Employer Sponsored 
Average Annual Drug Use 34.8 *28.8 *26.4
Average Unit Price $56.40 $53.30 $71.83 
Average Out-of-Pocket Cost $463.40 $411.80 $363.93 
Percent Out-of-Pocket to Total Cost 29.4 *35.3 26.23
Percent Prevalence of Any Diabetic Drug Use2 68.8 **54.9 51.83
M+C
Average Annual Drug Use 32.4 30.0 33.6
Average Unit Price $31.70 $28.40 *$38.50
Average Out-of-Pocket Cost $464.40 $456.50 $353.30 
Percent Out-of-Pocket to Total Cost 53.0 51.5 42.2
Percent Prevalence of Any Diabetic Drug Use2 73.6 **55.5 **60.5
** p<0.05 black non-Hispanics compared with white non-Hispanics and Hispanics compared with white non-Hispanics.
*p<0.10 black non-Hispanics compared with white non-Hispanics and Hispanics compared with white non-Hispanics.
1 Includes individuals reporting they have been told that they have diabetes.
2 Includes hormone such as insulin and oral hypoglycemic drugs.
NOTES: n=4.9 million. Unweighted n=1,196 white; n=218 black; n=154 Hispanic.
SOURCE: Centers for Medicare & Medicaid Services: Data from the Medicare Current Beneficiary Survey Cost and Use File, 1999.
prices dropped to relatively similar levels.
Out-of-pocket expenses also declined con-
siderably although dually eligible white
beneficiaries paid about twice as much for
their medications compared with Hispanics
(p>0.05) or black persons (p<0.05). Access
to diabetic agents became more similar
between white and Hispanic persons with
Medicaid, but not for black persons.
Employer-sponsored drug benefits
showed little ability to reduce racial/ethnic
disparities in drug use except in out-of-
pocket costs. With M+C coverage, we see a
leveling out of prescription use and spend-
ing across the three groups. Average drug
use is comparable between white persons
and Hispanics and only 10 percent lower
for black persons (p>0.05). Average unit
drug prices also look alike, although
Hispanics still used slightly more expen-
sive medications. Out-of-pocket costs and
generosity of coverage are nearly identical
for white and black persons with M+C cov-
erage, although Hispanics have slightly
less generous coverage (p>0.05). Access to
diabetic agents is still problematic, though,
as white persons are about 30 to 12 percent
more likely to use these medications than
black persons or Hispanics, respectively
(p<0.05).
In Table 4, we see similar patterns of
higher spending and medication use for
white beneficiaries with heart disease com-
pared with Hispanic and black persons
with the same condition, except for those
with M+C drug coverage. Without any pre-
scription plan, white persons filled four to
seven more prescriptions during the year
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Table 4
Prescription Use and Expenditures for Medicare Beneficiaries with Heart Disease1, by
Race/Ethnicity: 1999
Beneficiaries
Coverage2 White Black Hispanic
Total (in Millions) 11.75 0.95 0.80
No Coverage
Average Annual Drug Use 27.6 24.0 **20.4
Average Unit Price $36.70 $31.10 ** $46.8
Average Out-of-Pocket Cost $944.60 **$677.7 $752.60 
Percent Out-of-Pocket to Total Cost 93.6 93.1 100.0
Percent Prevalence of Any Heart Disease Drug Use2 76.7 ** 79.4 ** 67.2 
Medicaid
Average Annual Drug Use 44.4 39.6 *38.4
Average Unit Price $36.20 $31.80 $34.40 
Average Out-of-Pocket Cost $324.10 ** $168.6 **$200.2
Percent Out-of-Pocket to Total Cost 27.8 **19.9 **15.5 
Percent Prevalence of Any Heart Disease Drug Use2 85.1 **87.8 **89.1 
Employer Sponsored 
Average Annual Drug Use 31.2 27.6 27.6
Average Unit Price $55.30 *$46.5 ** $41.2
Average Out-of-Pocket Cost $422.00 $347.50 $307.60 
Percent Out-of-Pocket to Total Cost 31.6 34.1 32.9
Percent Prevalence of Any Heart Disease Drug Use2 81.7 ** 84.2 **85.5
M+C
Average Annual Drug Use 29.3 30.0 29.3
Average Unit Price $33.40 $32.20 $32.40 
Average Out-of-Pocket Cost $386.20 $409.10 $308.70 
Percent Out-of-Pocket to Total Cost 50.3 48.3 44.6
Percent Prevalence of Any Heart Disease Drug Use2 77.6 ** 88.6 ** 78.2
**p<0.05 black non-Hispanics compared with white non-Hispanics and Hispanics compared with white non-Hispanics.
*p<0.10 black non-Hispanics compared with white non-Hispanics and Hispanics compared with white non-Hispanics.
1 Includes individuals reporting they have been told that they have hypertension. It excludes hypertensive individuals with diabetes and/or heart disease.
2 Includes cardiac drugs, cardiovascular drugs, and diuretics.
NOTES: n=13.5 million. Unweighted n=3760 white; n=334 black; n=261 Hispanic.
SOURCE: Centers for Medicare & Medicaid Services: Data from the Medicare Current Beneficiary Survey Cost and Use File, 1999.
and spent 20 percent more compared with
black persons (p>0.05) and 28 percent
more compared with Hispanic persons
(p<0.05). Uninsured Hispanic beneficiaries
tended to fill more expensive medications,
but their access to common heart thera-
pies was the lowest: only 67 percent took
cardiac agents, cardiovascular medica-
tions, or diuretics during the year com-
pared with 77 to 79 percent of white and
black persons. Having Medicaid drug cov-
erage improved overall access to heart dis-
ease drugs for all groups, but the average
number of medications filled was still
much higher for white persons compared
with the other beneficiaries. Employer-
sponsored coverage consistently favored
white persons except in overall access to
heart drugs, which was relatively similar
(ranging from 81 to 85 percent). With M+C
coverage, disparity between racial and eth-
nic groups appeared to nearly disappear,
across measures of average use, average
unit price, out-of-pocket spending, and
access to any heart drugs. 
The M+C benefit observed previously
for minority beneficiaries is mixed in our
last example, those with hypertension
uncomplicated by diabetes or heart dis-
ease (Table 5). Here too, white beneficia-
ries without drug coverage used more
medications, spent more on their drug
therapies, and had more access to hyper-
tensive agents than the minority groups.
Medicaid coverage still tends to favor
white beneficiaries in terms of higher aver-
age drug use and better overall access to
medications related to the disease, although
70 HEALTH CARE FINANCING REVIEW/Winter 2003-2004/Volume 25, Number 2
Table 5
Prescription Use and Expenditures for Medicare Beneficiaries with Hypertension1, by
Race/Ethnicity:1999
Beneficiaries
Coverage2 White Black Hispanic
Total (in Millions) 5.83 0.66 0.54
No Coverage
Average Annual Drug Use 16.8 14.4 12.0
Average Unit Price $39.30 $33.20 *$31.4
Average Out-of-Pocket Cost $659.00 *$486.30 $526.10 
Percent Out-of-Pocket to Total Cost 98.2 99.5 100.0
Percent Prevalence of Any Hypertensive Drug Use2 75.1 **71.6 ** 58.8
Medicaid
Average Annual Drug Use 31.2 **21.6 **21.6
Average Unit Price $31.40 $34.20 **$39.6
Average Out-of-Pocket Cost $190.10 $110.30 **$80.4
Percent Out-of-Pocket to Total Cost 22.3 18.1 *13.0 
Percent Prevalence of Any Hypertensive Drug Use2 78.8 **67.2 **73.8
Employer Sponsored 
Average Annual Drug Use 21.6 14.4 25.2
Average Unit Price $55.40 $47.10 $46.80 
Average Out-of-Pocket Cost $326.80 $261.00 $457.40 
Percent Out-of-Pocket to Total Cost 33.6 32.7 36.4
Percent Prevalence of Any Hypertensive Drug Use2 76.6 ** 80.8 **75.3 
M+C
Average Annual Drug Use 21.6 *16.8 19.2
Average Unit Price $32.70 $30.70 $35.90 
Average Out-of-Pocket Cost $294.00 $201.50 $222.30 
Percent Out-of-Pocket to Total Cost 51.2 47.3 *42.6
Percent Prevalence of Any Hypertensive Drug Use2 69.7 **73.7 **58.4
**p<0.05 black non-Hispanics compared with white non-Hispanics and Hispanics compared with white non-Hispanics.
*p<0.10 black non-Hispanics compared with white non-Hispanics and Hispanics compared with white non-Hispanics.
1 Includes individuals reporting they have been told that they have hypertension.
2 Includes hormones such as insulin and oral hypoglycemic drugs.
NOTES: n=7.0 million. Unweighted n=1762 white; n=235 black; n=160 Hispanic.
SOURCE: Centers for Medicare & Medicaid Services: Data from the Medicare Current Beneficiary Survey Cost and Use File, 1999.
Hispanic and black persons had lower out-
of-pocket expenses. Employer-sponsored
coverage improved the number of filled
prescription for both white and Hispanic
persons, but not for black persons. However,
black persons with retiree drug benefits
paid the least out-of-pocket and had the
best access to hypertensive drugs. With
M+C drug coverage, the measures of med-
ication use fluctuated across the groups
and show no discernable pattern. White
persons with hypertension had the highest
average mediation use, Hispanics took the
most expensive drugs, but black persons
managed the best overall access to antihy-
pertensives. 
In Table 6, we tested whether the differ-
ences in medication use, spending and
access previously observed were due to
underlying population dissimilarities in
demographics, economic status, or health
status. After adjustment for these factors,
black and Hispanic persons still generally
filled fewer medications and spent less on
them than white persons, although some
differences narrowed with certain types of
drug coverage and diseases. Not having
drug coverage is particularly problematic
for black persons with diabetes who were
far less likely than white persons to fill any
diabetic agents (OR: 0.39).  On average,
black beneficiaries overall medication use
was 63 percent lower (p<0.10) and drug
spending was 69 percent less (p<0.05). In
contrast, uninsured black beneficiaries
with heart disease or hypertension experi-
enced about the same levels of drug use
and spending as white beneficiaries, and
access to condition-specific medications
appeared slightly better, although not sta-
tistically significant. Medicaid coverage
exerted surprisingly negative impacts for
chronically ill black beneficiaries. Black
Medicaid recipients with diabetes used
substantially fewer medications than white
recipients and had far lower access to
insulins or oral hypoglycemics. Neither did
Medicaid improve medication use for black
persons with heart disease whose patterns
are comparable to those without any drug
insurance, while access substantively wors-
ened for those with hypertension. Having
M+C or employer-sponsored drug cover-
age closed many gaps in medication use
and out-of-pocket spending between black
and white persons, across all three condi-
tions. Neither insurance type could improve
the compromised access that black per-
sons had to diabetic agents, although both
did increase the use of heart medications
and hypertensive agents. 
The impact of drug insurance on the
medication use of Hispanics is also sensitive
to condition type, although in ways that are
unique from that of black individuals.  Not
having drug coverage decreases overall
medication use, spending, and access for
Hispanics relative to white persons,
although particularly for those with hyper-
tension or heart disease. Medicaid coverage
does not appear to lessen the disparities,
except for out-of-pocket drug costs: dually
eligible Hispanic beneficiaries pay two to
three times less than white beneficiaries.
Under employer sponsored and M+C, gaps
in medication use and expenditure have
closed between Hispanic and white persons
with hypertension. However, differences
persist in those with diabetes and heart dis-
ease. Among the diabetics, Hispanics with
employer-sponsored coverage had lower
medication use compared with white per-
sons. Similarly among the diabetics,
Hispanics with M+C had lower access to
drugs specific to diabetes compared with
white persons. Among those with heart dis-
ease, out-of-pocket costs for Hispanics with
employer sponsored and M+C were one-
third lower than white persons. Total spend-
ing was significantly lower in Hispanics with
employer-sponsored coverage compared
with white persons. 
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DISCUSSION
The Medicare Program has dramatically
improved the health of older and disabled
persons by removing many financial barri-
ers, yet we know that some populations
have fared better than others by most mea-
sures of medical care use and outcomes.
Differences in the care of minority Medicare
beneficiaries have been puzzling to under-
stand as a problem of economic barrier
given the near-universal enrollment into
the program and uniformity of the benefit
(Mayberry, Milli, and Ofili, 2000). Recent
evidence in younger adult populations has
confirmed the view that health insurance
alone does not eliminate racial/ethnic dis-
parities and in fact may play a rather mod-
est role in ameliorating the differences.
Investigations into the primary drivers of
unequal use of medical services have
found that insurance influences access, but
much about racial/ethnic differences
remains unexplained (Weinick, Zuvekas,
and Cohen, 2000; Zuvekas, 1999; Zuvekas,
and Taliaferro, 2003). Nevertheless, drug
coverage status is far from uniform in the
Medicare population and we know type of
insurance strongly influences medication
use (Stuart, Shea, and Briesacher, 2000).
That black and Hispanic Medicare benefi-
ciaries use fewer or less expensive medica-
tions than white beneficiaries may still be a
problem grounded in socioeconomic caus-
es with far-reaching consequences. Not
being able to afford necessary medications
may explain, at least in part, why black and
Hispanic persons more often than white
persons experience some of the worst
effects of chronic illnesses. One study that
has linked drug coverage to racial/ethnic
differences in use of other medical care
services comes from an analysis of patients
who gained Medicare coverage through
the ESRD program (Daumit et al., 1999).
Medicare beneficiaries with ESRD entitle-
ment are among the few to receive
Medicare reimbursement for critical
outpatient medications—erythropoietin for
anemia and immunosuppressants. Daumit
et al. (1999) found that a three-fold differ-
ences in the use of clinical procedures by
patient ethnicity nearly disappeared follow-
ing the acquisition of the special ESRD
Medicare coverage. The researchers attrib-
uted the decline largely to the Medicare
benefit and concluded that equity in care
may be attainable for all Medicare benefi-
ciaries if coverage is truly comprehensive,
including for necessary prescription drugs.
Our study also detected statistically sig-
nificant and sometimes large differences in
the drug use and spending patterns of
chronically-ill Medicare beneficiaries by
race and ethnicity. These findings showed
wide variation that persisted even among
individuals with the same disease and
same type of prescription coverage. As
with studies of other medical services, we
found that minority beneficiaries tend to
get less of chronic medications compared
with the majority of beneficiaries who are
white. Drug coverage from M+C plans was
the most successful in eliminating the dif-
ferences although some remained, particu-
larly use of any diabetic agents by black
beneficiaries. What might explain the
improved equity in drug use associated
with M+C drug coverage? Speculations
include the mandatory assignment of a pri-
mary care doctor and disease management
programs, although the research is mixed.
Hargraves, Cunningham, and Hughes
(2001) did not find that managed care poli-
cies such as gatekeeper requirements
reduced racial/ethnic disparities in having
a usual source of care or visiting a physi-
cian in the last year. Haas et al. (2002)
found some improvements in preventive
care services for Hispanic persons in man-
aged care plans relative to FFS enrollees,
but not for black persons. Lastly, Schneider,
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Zaslavsky, and Epstein (2002) noted more
equitable use of β-blockers by race with
M+C enrollment, but only in plans with bet-
ter overall quality standards. 
This study has several limitations. First,
we used broad therapeutic classes in ana-
lyzing medication use. A more refined ther-
apeutic classification may provide more
information on the underlying pattern dif-
ferences observed here. Similarly, analyz-
ing access to new therapies could provide a
better marker for studying issues on dis-
parities because they are generally per-
ceived to be superior compared with older
therapies.
Second, our models explained less than
one-third of the variation in medication use
and access, which means other critical fac-
tors influence this behavior that were not
considered here. Notably, we did not con-
trol for differences in geography. We know
that Medicare minorities more often live in
urban areas (white persons 75 percent,
black persons 81 percent, Hispanics 86
percent) and in the south (white persons
33 percent, black persons 53 percent,
Hispanics 56 percent), while Hispanics
reside disproportionately in the west
(white persons 19 percent, black persons 6
percent, Hispanics 25 percent). As a relat-
ed limitation, we categorized our sample
into three racial/ethnic groups and this
classification may not accurately capture
variation in culture, biology, or values
(LaVeist, 1994). Lastly, we do not know if
white Medicare beneficiaries are overus-
ing medications, especially expensive
branded products, and it may be that
behavior which contributes to the large
racial/ethnic differences.
Notwithstanding these limitations, we
have shown that access to prescription
drugs is compromised for black and
Hispanic Medicare beneficiaries with con-
sistent need for medicines. Having some
form of drug coverage may help in easing
out-of-pocket burden, especially for people
with few personal resources, but it alone
will not eliminate racial/ethnic disparities.
Even Medicaid, the most generous of cov-
erage, could not erase the different med-
ication use patterns experienced by minori-
ties relative to white persons. We can only
speculate about the other potential causes
of disparity. A policy implication of our find-
ings is that the future Medicare expansion
into universal drug coverage should pro-
grammatically address closing the gaps in
medication use by race and ethnicity.
Surely one starting point is to more closely
study the features of M+C drug coverage
that appeared to create more equitable
access to drug therapy. Having a usual
source of care (either physician or clinic)
may be a promising first step as access to
primary care has been linked to less dis-
parity in other medical services (Williams,
Flocke, and Strange, 2001). Identifying the
mechanisms of managed care that promote
more equitable access is especially impor-
tant as black and Hispanic persons enroll
into these types of plans at higher rates
than do white persons (Cunningham and
Kohn, 2000) Lastly, our finding that
Hispanic beneficiaries tended to use more
expensive medications is puzzling and
requires more study, perhaps whether
preferences for branded medications are
related to ethnicity. 
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